InsidersTradesSigma
Track the Tempus AI, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Tempus AI, Inc. has published 263 insider filings. Market capitalisation: €12.4bn. The latest transaction was reported on 27 August 2026 (Cession). Among the most active insiders: LEFKOFSKY ERIC P. The full history is accessible without an account.
Tempus AI, Inc. has reported a total of 95 insider trading declarations in the last 90 days, with a total selling amount of approximately 88.88 million euros and no buying activity. The CEO and Chairman, Eric Lefkofsky, has made the most significant sales, totaling around 29.59 million euros across 45 declarations. Other notable insiders include Eric Lefkofsky in the role of Officer, Director, and 10% Stockholder, who has sold approximately 31.78 million euros in three transactions, and Ryan Fukushima, who has sold around 6.64 million euros in 14 declarations. Key recent sales include Lefkofsky's sale of approximately 14.18 million euros on August 25, 2026, and 9.43 million euros on July 28, 2026, both categorized as notices of proposed sales. Other sales by Lefkofsky and Fukushima were also recorded, with amounts ranging from approximately 1.75 million euros to 5.91 million euros.
Auto-generated summary, refreshed daily.Updated 3d ago
263
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€181m
200 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Tempus AI, Inc. Buy (bullish), based on 14 analysts. Average price target: US$63.36.
Fundamental score
Ranked 23,655 of 29,057 companies
29.7
score / 100
Value28
Quality31
FCF yld-2.2%
Earn yld-2.2%
EV/EBITDA·
ROE-67%
Gross mgn63%
Net mgn-19%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 August 2026
Declarations263 total
760 shares@ US$64.03Class A Common StockSEC:0001114357-26-000034:0
2,168 shares@ US$64.70Class A Common StockSEC:0001114357-26-000034:1
3,944 shares@ US$65.98Class A Common StockSEC:0001114357-26-000034:2
4,218 shares@ US$67.01Class A Common StockSEC:0001114357-26-000034:3
10,282 shares@ US$68.13Class A Common StockSEC:0001114357-26-000034:4
22,495 shares@ US$68.97Class A Common StockSEC:0001114357-26-000034:5
12,851 shares@ US$69.83Class A Common StockSEC:0001114357-26-000034:6
782 shares@ US$70.58Class A Common StockSEC:0001114357-26-000034:7
1,789 shares@ US$64.03Class A Common StockSEC:0001114357-26-000034:8
5,093 shares@ US$64.70Class A Common StockSEC:0001114357-26-000034:9
9,262 shares@ US$65.98Class A Common StockSEC:0001114357-26-000034:10
9,935 shares@ US$67.01Class A Common StockSEC:0001114357-26-000034:11
24,161 shares@ US$68.13Class A Common StockSEC:0001114357-26-000034:12
52,784 shares@ US$68.97Class A Common StockSEC:0001114357-26-000034:13
30,139 shares@ US$69.83Class A Common StockSEC:0001114357-26-000034:14
1,837 shares@ US$70.58Class A Common StockSEC:0001114357-26-000034:15
101 shares@ US$64.03Class A Common StockSEC:0001114357-26-000034:16
284 shares@ US$64.70Class A Common StockSEC:0001114357-26-000034:17
515 shares@ US$65.98Class A Common StockSEC:0001114357-26-000034:18
578 shares@ US$67.01Class A Common StockSEC:0001114357-26-000034:19
1,365 shares@ US$68.13Class A Common StockSEC:0001114357-26-000034:20
2,887 shares@ US$68.96Class A Common StockSEC:0001114357-26-000034:21
1,668 shares@ US$69.83Class A Common StockSEC:0001114357-26-000034:22
102 shares@ US$70.58Class A Common StockSEC:0001114357-26-000034:23
660 shares@ US$64.03Class A Common StockSEC:0001114357-26-000034:24
25 of 263 declarations
About Tempus AI, Inc.
Tempus AI, Inc. is a U.S.-based healthcare technology company listed on the NASDAQ in the United States, operating at the intersection of artificial intelligence, genomics, and precision medicine. Founded in 2015 by Eric Lefkofsky in Chicago, the company was built around the idea that large-scale clinical and molecular data can materially improve treatment decisions, initially in oncology and increasingly across broader disease areas. Tempus is headquartered in Chicago, Illinois, and its commercial footprint is primarily U.S.-focused, serving hospitals, cancer centers, laboratories, researchers, and biopharma partners. Tempus’ business model is built on complementary revenue streams. Its diagnostics segment offers molecular and genomic testing designed to better characterize tumors and other complex conditions. In parallel, the company commercializes data, analytics, and AI-powered tools that help users leverage proprietary clinical and molecular datasets for research, biomarker discovery, clinical trial matching, and decision support. This diagnostics-plus-data/software structure is a key differentiator versus traditional lab-testing companies and versus health-software vendors that lack Tempus’ owned data assets. From a competitive standpoint, Tempus aims to become a leading precision-medicine platform. Its investment case rests on the scale and quality of its data, the integration between testing and software, and its ability to partner with pharmaceutical companies, academic institutions, and health systems. The company has also been emphasizing new AI-enabled products and strategic partnerships to strengthen its position in patient stratification, screening, and care optimization. Recent milestones underscore the company’s momentum. On May 5, 2026, Tempus reported first-quarter 2026 revenue of $348.1 million, up 36.1% year over year, and it highlighted multiple collaborations, including initiatives with Bristol Myers Squibb and USC. In early May 2026, Tempus also announced a $400 million convertible senior notes offering intended to optimize its capital structure and reduce interest expense. In addition, the company was named by TIME as one of the 10 Most Influential Health and Life Science Companies of 2026. For investors, Tempus remains a high-growth healthcare technology name with meaningful upside tied to data monetization and product adoption, but also with the usual execution, reimbursement, regulatory, and commercialization risks inherent in precision medicine.
